Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation.

Autor: Falcone, Marco1 (AUTHOR) marco.falcone@unipi.it, Tiseo, Giusy1 (AUTHOR), Marchetti, Gabriele1 (AUTHOR), Kalo, Jona1 (AUTHOR), Galfo, Valentina1 (AUTHOR), Occhineri, Sara1 (AUTHOR), Almerigogna, Francesco1 (AUTHOR), Matucci, Tommaso1 (AUTHOR), Riccardi, Niccolò1 (AUTHOR), Suardi, Lorenzo Roberto1 (AUTHOR), Rina, Ines2 (AUTHOR), Sijoni, Ledja2 (AUTHOR), Caparello, Maria Costanza2 (AUTHOR), Cassano Cassano, Raffaella2 (AUTHOR), Del Giudice, Maria Livia2 (AUTHOR), Franciosa, Marinunzia2 (AUTHOR), Facella, Flaminia2 (AUTHOR), Tancredi, Gaspare2 (AUTHOR), Fazzi, Rita2 (AUTHOR), Galimberti, Sara2 (AUTHOR)
Zdroj: Leukemia & Lymphoma. Oct2024, Vol. 65 Issue 10, p1474-1481. 8p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje